Vijaya Diagnostic Centre Q4 Revenue Rises 27 Percent FY26 Revenue Crosses Rs 814 Crore

Vijaya Diagnostic Centre Q4 results for FY26 announced on 7 May 2026 confirmed the company’s highest-ever quarterly revenue in Q4 FY26, with revenue growing 26.6% year on year, driven by strong volume growth in both pathology and radiology segments. The Vijaya Diagnostic Centre Q4 results also mark the first year that the company’s full-year revenue surpassed Rs 800 crore, reaching Rs 814.2 crore up 19.5% year on year.

Investors tracking Vijaya Diagnostic Centre Q4 results FY26 will note that full-year FY26 profit after tax grew 20.3% to Rs 172.98 crore, maintaining strong profitability alongside revenue acceleration. The Vijaya Diagnostic Centre Q4 conducted 4.49 million tests in the quarter, up 18.5% year on year, with total footfall rising 15.8% to 1.21 million patients.

Get Free Stock Recommendations on Univest

Vijaya Diagnostic Centre Q4 FY26 Results at a Glance

Metric	Q4 FY26 / FY26	Change
Q4 Revenue Growth	+26.6% YoY	Highest-ever quarterly revenue
Q4 Tests Conducted	4.49 million	+18.5% YoY
Q4 Patient Footfall	1.21 million	+15.8% YoY
FY26 Revenue	Rs 814.2 crore	+19.5% YoY
FY26 EBITDA	Rs 336.94 crore	+23.3% YoY
FY26 PAT	Rs 172.98 crore	+20.3% YoY

Track live financials and analyst ratings on the Univest Screener.

Key Highlights from Vijaya Diagnostic Centre Q4 FY26

Revenue Crosses Rs 800 Crore in FY26

The Vijaya Diagnostic Centre Q4 results capped a landmark year with FY26 revenue surpassing Rs 800 crore for the first time, reaching Rs 814.2 crore at a 16.5% compound annual growth rate since listing. The Vijaya Diagnostic Centre Q4 highest-ever quarterly revenue reflects broad-based growth across pathology testing volumes and radiology utilisation in Telangana, Andhra Pradesh, and adjacent markets.

Test Volumes and Realisation Improvement

The Vijaya Diagnostic Centre Q4 conducted 4.49 million tests, up 18.5% year on year, reflecting both existing centre expansion and contribution from new centres opened during FY26. The Vijaya Diagnostic Centre Q4 average realisation per test improved 6.8% year on year and average realisation per footfall improved 9.3%, indicating positive product mix shift toward higher-value specialized diagnostic tests.

Pathology and Radiology Segment Balance

The Vijaya Diagnostic Centre Q4 growth was driven by both the pathology segment, which handled routine blood tests, hormone panels, and specialized assays, and the radiology segment including MRI, CT scan, and ultrasound services. The Vijaya Diagnostic Centre Q4 integrated diagnostics model, where patients can complete both lab and imaging services at the same centre, differentiates it from standalone pathology labs.

Risks to Monitor

• Geographic concentration: Vijaya Diagnostic Centre Q4 revenues are concentrated in Telangana and Andhra Pradesh, making the business sensitive to regional economic and competitive dynamics.
• Centre expansion execution: Scaling to new geographies outside the core South India market requires significant capital, brand building, and operational expertise.
• Competition from national chains: Dr. Lal PathLabs, Thyrocare, and Metropolis Healthcare are expanding in South India, creating competitive pressure on Vijaya Diagnostic Centre Q4 pricing and market share.
• Pricing pressure: Health insurance and corporate wellness contracts often involve competitive bidding that can compress realisations below retail pricing.

Conclusion

The Vijaya Diagnostic Centre Q4 results FY26 confirm a milestone year with revenue crossing Rs 800 crore at Rs 814.2 crore up 19.5%, PAT growing 20.3% to Rs 172.98 crore, and Q4 delivering the highest-ever quarterly revenue. The Vijaya Diagnostic Centre Q4 18.5% test volume growth and 6.8% realisation improvement confirm pricing power alongside volume growth.

For FY27, the most important variable for Vijaya Diagnostic Centre Q4 investors is whether the company can sustain revenue growth above 20% through geographic expansion beyond its South India stronghold, and whether the average realisation improvement trend continues as the product mix shifts toward specialized testing.

Download the Univest iOS App or Univest Android App for live Q4 results tracking and expert research.

Disclaimer: This article is for educational and informational purposes only and does not constitute investment advice. Univest analysts are SEBI-registered research analysts (SEBI RA: INH000012449). Investments in the securities market are subject to market risk. Consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions

What was Vijaya Diagnostic Centre Q4 FY26 revenue growth?

Vijaya Diagnostic Centre Q4 FY26 revenue grew 26.6% year on year, the highest-ever quarterly revenue for the company. FY26 full-year revenue was Rs 814.2 crore, up 19.5% YoY, the first year crossing the Rs 800 crore milestone.

What is Vijaya Diagnostic Centre FY26 PAT?

Vijaya Diagnostic Centre FY26 profit after tax was Rs 172.98 crore, up 20.3% year on year, with EBITDA at Rs 336.94 crore up 23.3%.

How many tests did Vijaya Diagnostic do in Q4 FY26?

Vijaya Diagnostic Centre Q4 conducted 4.49 million tests, up 18.5% year on year, with patient footfall rising 15.8% to 1.21 million patients.

What markets does Vijaya Diagnostic Centre serve?

Vijaya Diagnostic Centre Q4 primarily serves Telangana, Andhra Pradesh, and adjacent states in South India through its network of diagnostic centres offering integrated pathology and radiology services.

What is the Vijaya Diagnostic Centre Q4 FY27 outlook?

Vijaya Diagnostic Centre Q4 FY27 depends on sustaining test volume growth above 15%, realisation improvement through specialized test mix, and geographic expansion execution beyond the core South India market.

Recent Article

Why Is Liberty Shoes Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Shemaroo Entertainment Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Orchid Pharma Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Bajaj Holdings and Investment Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Prism Johnson Share Price Falling: Key Reasons and Investor Analysis 2026